BELGIUM, Wis., Jan. 5 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), a biological solutions company that develops products that produce a positive long term benefit to the agricultural and consumer market, announced today that it has entered into a non-binding letter of intent dated December 30, 2008 related to a proposed transaction with Modular Process Constructors LLC (dba MPS BioPharm) (the "Seller" or "BioPharm") to acquire all of the outstanding member interests of the Seller.
The proposed transaction is subject to satisfactory completion of due diligence by the Purchaser, the execution of a definitive agreement and the approval of both the board of directors and the members of Seller.
The non-binding terms of the letter of intent provide that all members of Seller would receive shares of the Purchaser in exchange for 100% of their interest of BioPharm. The terms include issuance of preferred stock with conversion rights at .25 per share in Mach One Corporation common stock.
There can be no assurance that any definitive agreement will be entered into, that any proposed transaction will be approved by the members of BioPharm or that any transaction will be completed as a result of the execution of the letter of intent.
Monte Tobin, CEO of Mach One Corporation commented, "This proposed acquisition of Modular Process Constructors, a systems company supplying pharmaceutical companies with processing skids, would fill out an important part of our future growth plans- dealing with world class customers and increasing our presence in the pharmaceutical space. Our business plan calls for us to eventually provide our Bridge(TM) product line into the human market and an acquisition now of BioPharm poises us for that future event on a global scale. This marks our third transaction in the 4th quarter with each transaction occurring at a substantially higher price. We anticipate our corporate development activities will continue to take place at increasingly higher valuations (non-dilutive) utilizing both organic and acquisition growth."
About Modular Process Constructors LLC (dba MPS BioPharm)
MPS BioPharm currently designs and builds skid based solutions to the biopharmaceutical markets. These skids allow the acceleration of production of biopharmaceutical products on a global basis.
About Mach One Corporation:
Mach One (www.machonecorp.com) currently manufactures and sells Bridge (TM) , a colostrums replacement, supplement and prophylactic, in sterile powder form, which can be administered orally or intravenously. VDx is also further developing a proprietary procedure to allow for large scale manufacturing of colostral replacement products for market that includes an added ingredient for elimination of mastitis and Johnnes disease.
Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.
|SOURCE Mach One Corporation|
Copyright©2009 PR Newswire.
All rights reserved